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Hugh Gelabert, MD, Juan Carlos Jimenez, MD, and Vicki Carter, RN, Los Angeles, Calif
Objectives: Endovenous closure is a common method to treat saphenous vein incompetence. Despite attempts to prevent
it, some patients have extension of thrombus above the ideal site of closure immediately below the epigastric vein.We have
developed a classification system for the level of saphenous vein closure to guide further therapy after endovenous
treatment.
Methods:A six-tier classification systemwas developed, based on thrombus proximity to the epigastric or femoral vein, and
an algorithm for treatment, based on level of closure was applied to all patients.
Results: Five hundred consecutive patients underwent radio-frequency ablation of the saphenous vein; it was
successfully closed in 498 (99.6%) patients. Thirteen patients (2.6%) experienced thrombus bulging into the femoral
vein or adherent to its wall, which was treated with anticoagulation. All of these patients had thrombus retraction
to the level of the saphenofemoral junction (SFJ) in an average of 16 days with concurrent anticoagulation. No
femoral deep venous thrombosis (DVT) occurred in the series. There was a significantly higher rate of proximal
thrombus extension in those patients with a history of DVT and those with a great saphenous vein (GSV) diameter
of >8 mm (P < .02).
Conclusions: A classification system for saphenous endovenous closure which extends above the epigastric vein has
been helpful in guiding management. A GSV diameter at the SFJ of >8 mm and a history of DVT results in
significantly higher rates of proximal thrombus extension into the femoral vein. A short course of LMWH, until clot
retracts back into the saphenous vein, is therapeutic. Management of the patients with thrombus flush with the
femoral vein wall still needs to be defined, but the outcome from these patients is generally benign. ( J Vasc Surg
2010;52:388-93.)Endovenous ablation of the saphenous vein has be-
come the most common procedure for treatment of
symptomatic reflux.1 A recognized complication of this
procedure is extension of thrombus from the great sa-
phenous vein (GSV) into the deep venous system follow-
ing closure. A report by Hingorani et al of a 16% inci-
dence of deep venous thrombosis following saphenous
radio-frequency ablation (RFA) led to a re-examination
of this technique, as well as a recommendation that
routine postprocedure ultrasound be used to detect ex-
tension of thrombus into the deep venous system.2 Cur-
rently, there is no evidence-based recommendation for
the treatment of thrombus that extends above the opti-
mal closure level below the epigastric vein.
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388Since the 2004 report, we have uniformly obtained
duplex ultrasound within 48 to 72 hours of the proce-
dure to determine the incidence of deep venous throm-
bosis (DVT) following RFA with contemporary en-
dovenous closure devices and techniques.2 As a result of
this practice, we have been able to develop a classification
system for levels of endovenous closure of the GSV.
This system was associated with a treatment algorithm
for saphenous thrombosis occurring in or immediately
adjacent to the femoral vein. The goal of this system was
to help determine factors associated with post-RFA
thrombosis immediately adjacent to or into the femoral
vein.
In this study, we report on our use of the classification
system for level of vein closure, propose an algorithm for
management of patients based on level of vein closure, and
review the results of implementing this system on 500
consecutive patients. We also assess the risk factors that may
help determine which patients are most likely to require
post-RFA duplex surveillance.
METHODS
We developed a classification system for endovenous
closure levels of the GSV. (Fig 1) A range of progressive
closure levels, classified as levels 1 to 6, was developed
based on the relationship to the epigastric vein and
proximity to the femoral vein. Level 1 represented clo-
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Level 2 represented closure with thrombus extension
flush with the orifice of the epigastric vein. Level 3
represented closure with thrombus extension flush with
the saphenofemoral junction. Level 4 represented clo-
sure with thrombus bulging into the common femoral
vein (CFV). Level 5 represented closure with proximal
thrombus extension adherent to the adjacent wall of the
CFV past the saphenofemoral junction (SFJ). Level 6
represented closure with proximal thrombus extension
into the CFV, consistent with a DVT. We then applied a
treatment algorithm for each level, from closure levels 1
to 6.
We analyzed 500 consecutive patients who underwent
GSV RFA from 2005 to 2009 to determine the impact of
the classification system and treatment algorithm on out-
come. Preprocedural risk factors, vein characteristics, and
postprocedure level of occlusion and treatment were ana-
lyzed.
All data are presented as mean values. Statistical analysis
included two-tailed Fisher exact test for calculation of P
values for categorical variables. (P  .05 significant) A
two-tailed, unpaired Student t-test was used to calculate P
values for all continuous variables. The modified Wald’s
method was used to calculate 95% confidence intervals for
categorical data.
Selection criteria of patients for RFA. Consecutive
patients who met the criteria for treatment of saphenous
Fig 1. Classification system of closure level for radio-fr
corresponding treatment algorithms.reflux were the basis of this report. Their CEAP classifi-cation ranged from 2 to 5. Patients with symptomatic
saphenous or tributary veins were required to have
been treated with nonprocedural therapy for at least 3
months prior to consideration of RFA. Medical therapy
included compression support hose, leg elevation, and
avoidance of prolonged standing. Persistent symptoms
which interfered with daily living were required for RFA
treatment. Patients with lipodermatosclerosis and ve-
nous ulcers were initially treated with elastic compres-
sion for a minimum of three months before they were
eligible for RFA.
Saphenous dilatation and reflux was determined by
duplex ultrasound in our vascular lab. Reflux in the proxi-
mal GSV was measured in both the supine and standing
positions. Greater than 1.5 seconds of reflux in either
position was required for GSV RFA treatment eligibility. In
addition, the target vein had to have a minimum diameter
of 3 mm in the refluxing segments.
RFA clinical environment. RFA was performed in
both an ambulatory surgery center and an office-based
environment, with the site of the procedure based on
extent of venous disease, patient wishes, and insurance
authorization. Local anesthesia and monitored intrave-
nous anesthesia were both used. No patient was treated
under general anesthesia. Concomitant procedures were
often performed with the RFA procedure. The decision
on concomitant procedures was left to the surgeon and
patient and based on numerous preference factors. Mi-
ncy ablation (RFA) of the greater saphenous vein withequecrophlebectomy and light-assisted stab phlebectomy
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comitantly.3 Only RFA cases treating the GSV were
included in this series.
Warfarin was discontinued 4 to 5 days preprocedure
and LMWH used in those patients with mechanical heart
valves or those with a history of pulmonary embolus. Clo-
pidogrel was discontinued 7 days preprocedure and aspirin
was not discontinued.
RFA technique. All patients were treated using a
standard technique which adhered to the indications for
use for RFA of the GSV. Procedures were performed using
a tilt table and portable duplex ultrasound. Percutaneous
placement of the catheter in the below-knee GSV was the
access site of choice. If this vein was inadequate for access,
the above-knee GSV was used for endovenous closure.
Once access was obtained, the Closure or ClosureFast
catheter (VNUS Medical Technologies, San Jose, Calif)
was advanced up the saphenous vein to a point 2.0 to 2.5
cm caudal to the saphenofemoral junction. The relation of
the catheter tip to the epigastric vein was noted to be
variable and often could not be ascertained; placement
below the epigastric vein was not used as criteria for cath-
eter positioning.
Liberal injection of standard tumescent solution (con-
sisting of saline, xylocaine, and epinephrine) was placed
around the saphenous vein from the catheter insertion site
to the saphenofemoral junction. Both Closure (85°C with
pullback) and ClosureFast catheters (120°C ) were used for
endovenous closure, and the transition from one catheter
to the other occurred when the ClosureFast catheter be-
came commercially available. Once the vein was treated,
patients were placed in a compressive dressing with local-
ized pressure along the GSV.
Post-RFA management. Duplex ultrasound was
performed 48 to 72 hours postprocedure after removal
of all dressings. No further dressing was used in most
patients. If there was an abnormal duplex ultrasound
result (level 3-6), treatment was initiated and repeat
duplex ultrasound was performed weekly until the
thrombus retracted and stabilized at a level 2 to 3.4 No
further imaging was performed after this finding and
discontinuation of anticoagulation.
Management of levels of closure. Patients with level
1 or 2 closure 48 to 72 hours postprocedure had no further
management of their GSV, although they were instructed
to return for a final evaluation of their venous disease 6
weeks postprocedure. Patients with level 3 closure were
managed with both observation and repeat duplex ultra-
sound to assess for progression of thrombus, or with low
molecular weight heparin (LMWH) as an outpatient. The
LMWH was discontinued when the thrombus had re-
tracted to a level 2 or 3. No further anticoagulation was
recommended or used.
Patients with level 4 closures were treated with
LMWH uniformly, until the thrombus retracted flush
with or into the saphenous vein. No further anticoagu-
lation was used after clot retraction. Patients with level 5
closures were treated with outpatient LMWH, which wasused until the thrombus retracted to level 3 and then
discontinued. Although no patient had a level 6 closure,
it would have been treated with LMWH and coumadin
for 3 months.
RESULTS
Five hundred consecutive patients underwent RFA of
the saphenous vein from December 2005 until July 2009;
335/500 (67%) of patients had the procedure using the
ClosureFast catheter. Compliance with the management
protocol postprocedure was universal. One hundred per-
cent had a postprocedure duplex ultrasound from 1 to 4
days postprocedure (90% on day 2). Seventy-six percent
of patients were women and 89% had CEAP 2 classification
of their venous disease. Risk factors for potential complica-
tions from endovenous closure included prior DVT in 2.2%
(11/500) and use of anticoagulation/antiplatelet medica-
tions in 14.6% (warfarin [5.4%), Clopidogrel [1.2 %], and
aspirin [7.6%]).
Level of closure. Four hundred ninety-eight of 500
(99.6%) patients had successful occlusion of the great
saphenous vein confirmed by duplex ultrasound on their
first postprocedure visit. Greater than 90% had closure
below the epigastric vein; no patient had a level 6 throm-
bosis that completely occluded the femoral vein (Table
I). The mean age of all patients who underwent RFA was
53.0  14.9 years. Those who had a level of thrombosis
(4 or 5), which required anticoagulation had a mean age
of 57.1  11.5 years compared with a mean age of 52.9 
14.9 years for those with a lower level of closure (1-3),
which was not statistically different (P  .33). Of the 11
patients who had a history of DVT, two developed a level
4 or 5 closure requiring anticoagulation. Both of these
patients had their DVT diagnosis in the remote past and
the location of the DVT was not known. Neither of these
patients were being treated with anticoagulation at the
time of the procedure. A history of DVT was a statisti-
cally significant risk factor for the need for anticoagula-
tion (P  .029).5
The mean preoperative diameter of the saphenous
Table I. Level of closure of GSV after RFA
Closure level N %
1 453 92.4
2 3 0.6
3 21 4.3
4 8 1.6
5 5 1.0
6 0 0.0
GSV, Great saphenous vein; RFA, radio-frequency ablation.
The level of closure of the saphenous vein post-RFA was below the epigas-
tric vein in 92% of patients. When the closure extended above the
epigastric vein, the thrombus usually migrated to a position flush with the
femoral vein.vein in all patients who underwent RFA was 7.34  2.99
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3 and did not require anticoagulation had a mean diam-
eter of 7.29  2.93 mm, while those with a level 4 or 5
closure had a mean diameter of 10.46  3.61 mm. (Fig
2, B and C) Patients with a saphenous vein diameter
greater than 8 mm had a significantly higher risk of
closing their vein at a level that required anticoagulation
(level 4-5) (P  .02, Table II).
DISCUSSION
The goal of endovenous ablation of the GSV is to
Fig 2. Distribution of diameters of the great saphenous vein
at the saphenofemoral junction with subgroup populations
based on closure level. A, The mean diameter of the saphe-
nous vein for all patients who underwent RFA was 7.34 mm. B,
The mean diameter of the saphenous vein in patients with level
1-3 closure who did not require anticoagulation was 7.29 mm.
C, The mean diameter of the saphenous vein in patients
with level 4 or 5 closure who did require anticoagulation was
10.46 mm.close the proximal saphenous vein at the saphenofemoraljunction, ideally below the epigastric vein, while avoid-
ing extension of thrombus into the femoral vein, causing
DVT. Numerous reports from large databases have
demonstrated the high success rate of closure using both
laser and radio-frequency catheters. However, other
than a report of the high risk of venous thrombosis and
an article suggesting a classification system for manage-
ment of patients who develop venous thrombosis of the
femoral vein, there have been few reports on levels of
closure of the saphenous vein.6,7 Furthermore, there is
little literature regarding the management of patients
who have had closure/thrombus extend above the epi-
gastric vein, either flush with the femoral vein or extend-
ing into the femoral vein. Since our policy was instituted
to routinely perform duplex scan of the GSV within 48 to
72 postprocedure, we have encountered patients with
every combination of closure level. We have had con-
cerns about patients whose closure extends flush with
the femoral vein, and particular concerns about throm-
bus that bulges or extends from the saphenous vein
into the femoral vein. Although there should be uniform
agreement about the management of patients who have
Table II, A. Incidence of level 3, 4, or 5 closure by GSV
diameters (relationship between vein diameter and the
development of level 3, 4, or 5 closure)
Diameter (GSV) N
Incidence of level
3, 4, 5 95% CI
3-5.0 mm 3 1.77% 0.09%-6.62%
5.1-8.0 mm 9 4.88% 2.56%-8.85%
8.1-10.0 mm 6 6.9% 2.9%-14.5%
10.0 mm 14 23.33%a 14.32%-35.6%
CI, Confidence interval; GSV, great saphenous vein.
This table demonstrates that saphenous vein size is an important
factor in proximal thrombus extension. For veins 8 mm, incidence
of level 3, 4, or 5 closure is statistically different from entire group
(P  .017).
aP  .017 vs total group.
Table II, B. Incidence of level 4 or 5 closure by GSV
diameters
Diameter (GSV) N
Incidence of level
4, 5 95% CI
3-5.0 mm 0 0% 0%-3.9%
5.1-8.0 mm 4 1.95% 0.58%-5.1%
8.1-10.0 mm 3 3.45% 0.76%-10.1%
10.0 mm 6 10% 4.3%-20.5%
8 mm 4 1.89% 0.77%-4.15%
8 mm 9 6.12%a 3.1%-11.38%
CI, Confidence interval; GSV, great saphenous vein.
For level 4 or 5 closure, 8-10 mm and 10 mm saphenous veins are not
significantly different from the entire group (P  .169); however, size is a
significant risk of level 4 or 5 closure if groups are separated into 8 mm
(P  .012).
aP  .012 vs 8 mm.DVT with occlusion of the common femoral vein, the
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not occluding it, have lead to our decision to develop
a classification system of levels of closure and suggest
an algorithm for management of different levels of
closure.
This report confirms the high success rate of en-
dovenous closure, provided a standardized method of
endovenous closure is used. The major risk factors asso-
ciated with development of level 4 and 5 thrombus
bulging into the femoral vein are patients who have a
prior history of DVT, whether or not they are currently
on anticoagulation, and the size of the saphenous vein at
the SFJ. Age and use of anticoagulation were not risk
factors in our patient cohort. These risk factors have been
variably reported in other series, and the data were not
statistically significant due to the small sizes of their
series.
In this series, with a wide range of saphenous vein
sizes, we achieved closure of the proximal saphenous vein
in 99.6% of patients. We also had a low incidence of
thrombus either attached to the edge of the femoral vein
wall or bulging into the femoral vein. We did not have
any cases of femoral vein thrombosis. When thrombus
bulges into the femoral vein, it has the potential to
retract over time, whether or not the patient is anticoag-
ulated. We had no patient with extension of thrombus
into the femoral vein, causing DVT, whether the patient
was managed expectantly or anticoagulated with LMWH.
All 13 patients who had level 4 and level 5 extension of
thrombus into the femoral vein retracted their thrombus
to a level 3 or 2 with anticoagulation in an average of
sixteen days, and none developed extension into the
femoral vein and DVT.
The most challenging decision is in patients who
have level 3 thromboses, flush with the femoral vein; the
risk of the thrombus extension into the femoral vein is
unclear. Only 21 (4.3%) had closure at this level, an
inadequate number to allow definitive recommenda-
tions, particularly since both close observation and anti-
coagulation with LMWH were used in approximately
equal numbers. Since the treatment of these patients has
not been resolved by other large clinical series, we al-
lowed the clinician treating the patient to make the
decision regarding anticoagulation. In our series, with
use of either close observation or LMWH, there was no
case of extension of thrombus into the femoral vein.
Further studies are needed to determine the risk of
extension from a level 3 into the femoral vein without
anticoagulation. Until those studies are performed, we
recommend an individualized approach.
CONCLUSION
Based on our experience with 500 patients who
underwent RFA for saphenous reflux, the data suggest
that patients with vein diameters 8 mm and no history
of DVT may be able to forego follow-up ultrasound. Infact, we found only two patients with a level 4 to 5
closure and a GSV diameter of 8 mm or smaller, which
represented 0.7% of all patients with GSV diameters of 8
mm or less. Those patients with a history of DVT or a
saphenous vein 8 mm should undergo a single duplex
scan postprocedure to determine the level of closure and,
if it is a level 4 or 5 closure, anticoagulation should be
instituted with LMWH. In these patients, when closure
is just above or below the epigastric vein but not flush
with the femoral vein, no further surveillance is required.
When the closure is flush with the femoral vein, the
clinician has the option of either close observation using
repeated duplex ultrasound, or short term anticoagula-
tion with low molecular weight heparin, as an outpa-
tient. When the thrombus in the saphenous vein is
bulging into the femoral vein or adherent to the adjacent
femoral vein wall, patients should be treated with
LMWH until the thrombus retracts and at least becomes
flush with the femoral vein. This will occur in an average
of 16 days. Although we encountered no patient with
occlusion of the femoral vein, we recommend longer-
term anticoagulation in these patients, similar to that
used for DVT. Using this classification system and treat-
ment algorithm, it is unlikely that patients will develop
DVT or pulmonary embolism following RFA for saphe-
nous vein reflux.
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